Which has better valuation and earnings, KALA or IBIO?

iBio has higher revenue and earnings than KALA BIO. iBio is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A iBio $400K 171.40 -$18.38M -$0.58 N/A

Is KALA or IBIO more profitable?

iBio's return on equity of -53.86% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% iBio N/A -53.86% -46.48%

Do analysts recommend XBIT or KALA?

KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 157,175.40%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, XBIT or KALA?

XBiotech is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is XBIT or KALA more profitable?

XBiotech's return on equity of -26.10% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% KALA BIO N/A -1,336.10% -94.85%

Which has stronger valuation and earnings, HYFT or KALA?

MindWalk has higher revenue and earnings than KALA BIO. MindWalk is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MindWalk $17.59M 3.82 -$21.69M -$0.20 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is HYFT or KALA more profitable?

KALA BIO has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -66.79% -69.37% -39.74% KALA BIO N/A -1,336.10% -94.85%

Is PLRX or KALA more profitable?

Pliant Therapeutics' return on equity of -58.11% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% KALA BIO N/A -1,336.10% -94.85%

Which has better earnings & valuation, MNOV or KALA?

MediciNova has higher revenue and earnings than KALA BIO. MediciNova is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediciNova $410K 159.66 -$12M -$0.23 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is MNOV or KALA more profitable?

KALA BIO has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets MediciNova -1,962.98% -27.28% -25.24% KALA BIO N/A -1,336.10% -94.85%

KALA BIO (KALA) Competitors

$0.74 +0.00 (+0.42%)

Closing price 07/22/2026 04:00 PM Eastern

Extended Trading

$0.71 -0.03 (-3.46%)

As of 07:49 AM Eastern

Compare

KALA vs. IBIO, XBIT, HYFT, PLRX, and MNOV

Should you buy KALA BIO stock or one of its competitors? MarketBeat compares KALA BIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KALA BIO include iBio (IBIO), XBiotech (XBIT), MindWalk (HYFT), Pliant Therapeutics (PLRX), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry.

How does KALA BIO compare to iBio?

KALA BIO (NASDAQ:KALA) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, iBio had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for iBio and 0 mentions for KALA BIO. iBio's average media sentiment score of 1.05 beat KALA BIO's score of 0.98 indicating that iBio is being referred to more favorably in the news media.

Company	Overall Sentiment
KALA BIO	Positive
iBio	Positive

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

iBio's return on equity of -53.86% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
iBio	N/A	-53.86%	-46.48%

KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market. Comparatively, iBio has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

iBio has higher revenue and earnings than KALA BIO. iBio is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
iBio	$400K	171.40	-$18.38M	-$0.58	N/A

KALA BIO currently has a consensus price target of $1,158.33, suggesting a potential upside of 157,175.40%. iBio has a consensus price target of $5.00, suggesting a potential upside of 262.32%. Given KALA BIO's higher possible upside, equities analysts clearly believe KALA BIO is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

iBio beats KALA BIO on 12 of the 15 factors compared between the two stocks.

How does KALA BIO compare to XBiotech?

XBiotech (NASDAQ:XBIT) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

55.7% of XBiotech shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 30.8% of XBiotech shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, KALA BIO's average media sentiment score of 0.98 beat XBiotech's score of 0.00 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
XBiotech	Neutral
KALA BIO	Positive

XBiotech has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market.

XBiotech's return on equity of -26.10% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
KALA BIO	N/A	-1,336.10%	-94.85%

KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 157,175.40%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XBiotech is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

Summary

XBiotech and KALA BIO tied by winning 6 of the 12 factors compared between the two stocks.

How does KALA BIO compare to MindWalk?

MindWalk (NASDAQ:HYFT) and KALA BIO (NASDAQ:KALA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

KALA BIO has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
KALA BIO	N/A	-1,336.10%	-94.85%

MindWalk has higher revenue and earnings than KALA BIO. MindWalk is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.82	-$21.69M	-$0.20	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

6.7% of MindWalk shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MindWalk has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its stock price is 335% less volatile than the broader market.

In the previous week, MindWalk had 4 more articles in the media than KALA BIO. MarketBeat recorded 4 mentions for MindWalk and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.98 beat MindWalk's score of -0.61 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
MindWalk	Negative
KALA BIO	Positive

MindWalk currently has a consensus price target of $5.00, indicating a potential upside of 247.22%. KALA BIO has a consensus price target of $1,158.33, indicating a potential upside of 157,175.40%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MindWalk beats KALA BIO on 11 of the 16 factors compared between the two stocks.

How does KALA BIO compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

KALA BIO has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	43.11	-$149.34M	-$1.84	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

In the previous week, Pliant Therapeutics had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.98 beat Pliant Therapeutics' score of 0.00 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
KALA BIO	Positive

Pliant Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, suggesting that its stock price is 335% less volatile than the broader market.

Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 172.73%. KALA BIO has a consensus price target of $1,158.33, suggesting a potential upside of 157,175.40%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pliant Therapeutics' return on equity of -58.11% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
KALA BIO	N/A	-1,336.10%	-94.85%

Summary

Pliant Therapeutics beats KALA BIO on 8 of the 13 factors compared between the two stocks.

How does KALA BIO compare to MediciNova?

MediciNova (NASDAQ:MNOV) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

MediciNova has higher revenue and earnings than KALA BIO. MediciNova is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	159.66	-$12M	-$0.23	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

MediciNova has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market.

In the previous week, MediciNova had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for KALA BIO. MediciNova's average media sentiment score of 1.31 beat KALA BIO's score of 0.98 indicating that MediciNova is being referred to more favorably in the media.

Company	Overall Sentiment
MediciNova	Positive
KALA BIO	Positive

MediciNova presently has a consensus target price of $8.33, indicating a potential upside of 526.57%. KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 157,175.40%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

KALA BIO has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
KALA BIO	N/A	-1,336.10%	-94.85%

Summary

MediciNova beats KALA BIO on 12 of the 16 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALA vs. The Competition

Export

Metric	KALA BIO	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.63M	$3.68B	$7.01B	$12.68B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-0.01	21.19	26.82	23.95
Price / Sales	N/A	306.01	576.26	115.11
Price / Cash	N/A	155.65	50.60	60.45
Price / Book	0.06	8.00	10.56	6.16
Net Income	-$26.98M	$23.81M	$3.60B	$331.73M
7 Day Performance	-13.06%	-1.22%	-1.34%	-0.92%
1 Month Performance	-76.39%	-1.36%	-0.29%	-2.23%
1 Year Performance	-99.74%	34.77%	18.96%	14.79%

KALA BIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALA KALA BIO	2.3639 of 5 stars	$0.74 +0.4%	$1,158.33 +157,175.4%	-99.7%	$13.63M	N/A	N/A	30	Gap Up
IBIO iBio	2.8064 of 5 stars	$1.43 -0.7%	$5.00 +249.7%	N/A	$71.54M	$400K	N/A	100	Positive News
XBIT XBiotech	0.3194 of 5 stars	$2.29 flat	N/A	-26.3%	$69.82M	N/A	N/A	100	Positive News
HYFT MindWalk	2.7572 of 5 stars	$1.49 +0.7%	$5.00 +235.6%	N/A	$69.13M	$17.59M	N/A	80	News Coverage Earnings Report Analyst Forecast
PLRX Pliant Therapeutics	1.863 of 5 stars	$1.12 +2.8%	$3.00 +167.9%	-29.9%	$67.49M	$1.58M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KALA BIO (KALA) Competitors